权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Analysis of CD133 positive cells in pituitary adenoma

垂体腺瘤CD133阳性细胞分析

基本信息

批准号：
21591875
负责人：
ARITA Kazunori
金额：
$ 2.75万
依托单位：
Kagoshima University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2009
资助国家：
日本
起止时间：
2009 至 2011
项目状态：
已结题

项目摘要

Stem-like cells in tumors are capable of self-renewal and pluri-differentiation ; they are thought to play important roles in tumor initiation and maintenance. Stem-like cells in malignant glioma express CD133. We examined samples from human pituitary adenoma, a generally benign neoplasm, for CD133 expression using routine immunohistochemical and biochemical methods.Our study of 70 pituitary adenomas(clinically nonfunctioning adenomas and growth hormone-, prolactin-, adrenocorticotropic hormone-, and thyroid stimulating hormone producing adenomas) showed that 18(25. 7%) expressed CD133. This rate was higher in clinically non-functioning(33.3%) than functioning adenomas(12.0%)(p=0.085). Real-time PCR assay revealed the expression of CD133 mRNA in samples immunohistochemically positive for CD133. Neither the patient age and gender, nor the tumor size or postoperative recurrence rate correlated with CD133 positivity. CD133^+cells ubiquitously coexpressed CD34, nestin, and VEGFR2(KDL1). S-100 and GFAP were not coexpressed with CD133. Chromogranin A, Pit-1, SF-1, and NeuroD1 were immune-negative, indicating that CD133^+cells did not have the potential to differentiate into functional endocrine cells.Our data suggest that the expression of CD133 in pituitary adenomas is related to immature endothelial progenitor cells that may play a role in the neovascularization of pituitary adenomas. Further studies are needed to elucidate the significance of CD133^+ cells with respect to neovascularization and their sustainable growth in pituitary adenomas.

肿瘤中的干细胞具有自我更新和多向分化的能力，被认为在肿瘤的启动和维持中发挥重要作用。恶性胶质瘤中干细胞样细胞表达CD133。我们用常规的免疫组织化学和生化方法检测了人类垂体腺瘤(一种通常为良性的肿瘤)的CD133表达。我们对70例垂体腺瘤(临床上无功能的腺瘤和生长激素、催乳素、促肾上腺皮质激素和促甲状腺激素的腺瘤)的研究表明，18(25。7%)表达CD133。临床无功能腺瘤的这一比率(33.3%)高于功能性腺瘤(12.0%)(p=0.085)。实时荧光定量聚合酶链式反应显示CD133在免疫组织化学阳性的标本中有表达。CD133阳性与患者年龄、性别、肿瘤大小或术后复发率无关。CD133^+细胞普遍表达CD34、Nestin和VEGFR2(KDL1)。S-100和胶质纤维酸性蛋白未与CD133共表达。嗜铬粒蛋白A、Pit-1、SF-1和NeuroD1均为免疫阴性，提示CD133~+细胞不具备向功能性内分泌细胞分化的潜能，提示CD133在垂体腺瘤中的表达与未成熟的内皮祖细胞有关，可能在垂体腺瘤的新生血管形成中起作用。CD133^+细胞在垂体腺瘤新生血管形成及其可持续生长中的意义尚需进一步研究。